Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00001444 · ClinicalTrials.gov registry record · Phase 1
A Phase I Trial of Continuous Infusion UCN-01 in Patients With Refractory Neoplasms
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 51
- Enrollment target
NCT00001444: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00001444 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 51 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00001444, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 51 participants
- Enrollment target
Study Summary
This is a dosage escalation study to estimate the maximum tolerated dose of staurosporine analogue UCN-01. Groups of 3 to 6 patients receive a 72-hours intravenous continuous infusions of UCN-01 from day 1 to day 4 of each cycle the first cycle only, and over 36-hours on subsequent cycles. The side effects are allowed to disappear for up to 28 days. This cycle is repeated after evaluations and follow-ups, which are every 4 weeks, as long as the patient benefits.
Interventions
- DRUG 7-hydroxystaurosporine (UCN-01)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 1995-08 |
| Est. Completion | 2002-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00001444
The ClinicalTrials.gov registry entry for NCT00001444 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 7-hydroxystaurosporine (UCN-01) is the first listed.
NCT00001444 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00001444 about?
NCT00001444 is a clinical study titled "A Phase I Trial of Continuous Infusion UCN-01 in Patients With Refractory Neoplasms". This is a dosage escalation study to estimate the maximum tolerated dose of staurosporine analogue UCN-01. Groups of 3 to 6 patients receive a 72-hours intravenous continuous infusions of UCN-01 from day 1 to day 4 of each cycle the first cycle only, and over 36-hours on subsequent cycles. The side ...
What is the current status of trial NCT00001444?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 51 participants. The study started on 1995-08. Estimated completion is 2002-05.
What interventions are being tested in trial NCT00001444?
The interventions under investigation include: 7-hydroxystaurosporine (UCN-01) (DRUG).
Who is sponsoring clinical trial NCT00001444?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.